Ratings Shockwave Medical, Inc.

Equities

SWAV

US82489T1043

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-15 pm EDT			5-day change	1st Jan Change
330.9 ^USD	-0.04%		+0.07%	+73.63%

May. 13	Johnson & Johnson Offering Notes to Help Fund Shockwave Medical Acquisition	MT
May. 06	Shockwave Medical, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths

According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
The group's activity appears highly profitable thanks to its outperforming net margins.
Thanks to a sound financial situation, the firm has significant leeway for investment.
Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
Over the past four months, analysts' average price target has been revised upwards significantly.
Considering the small differences between the analysts' various estimates, the group's business visibility is good.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

With an expected P/E ratio at 63.35 and 53.82 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
Based on current prices, the company has particularly high valuation levels.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The company is highly valued given the cash flows generated by its activity.
The overall consensus opinion of analysts has deteriorated sharply over the past four months.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	ESG Refinitiv
SHOCKWAVE MEDICAL, INC.	+73.63%	12.43B	B-
PENUMBRA, INC.	-18.62%	8.09B	C+
MASIMO CORPORATION	-0.90%	6.12B	C-
JIANGSU YUYUE MEDICAL EQUIPMENT & SUPPLY CO., LTD.	+14.66%	5.59B	D+
GETINGE AB	-14.69%	5.47B	B
APT MEDICAL INC.	+39.93%	5.23B	-
ASAHI INTECC CO., LTD.	-15.15%	4.1B	B-
INARI MEDICAL, INC.	-27.62%	2.65B	C
SKAN GROUP AG	+1.36%	1.99B	-
SHENZHEN YHLO BIOTECH CO., LTD.	+5.99%	1.96B	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes